Esketamine is a form of ketamine that can be used via a nasal spray and that has just been recommended for approval by the FDA to treat severe depression. While esketamine does not require an infusion, it must be administered in a health care setting where patients can be monitored for up to two hours. Based on our research, we believe that intravenous delivery of ketamine is more reliable and less likely to cause severe side effects. However, esketamine nasal spray provides a viable alternative treatment method for those patients uncomfortable with an IV. Currently, we only offer Ketamine via infusions. We do not currently offer intranasal Esketamine and are adding this option soon.
If ketamine treatment is prescribed, all scheduled treatments are attended by a qualified professional under close physiologic monitoring. The framework for ketamine-assisted therapies is structured to insure an integrated and effective experience.